Call for Balancing the Risks and Benefits of Immunotherapeutic Agents for Lymphoma during the COVID-19 Pandemic

참고문헌 (10)

1. Harrison SL, "Comorbidities associated with mortality in 31, 461 adults with COVID-19 in the United States : a federated electronic medical record analysis", PLoS Med, 17, pp.e1003321~ (2020)
2. Vijenthira A, "Outcomes of patients with hematologic malignancies and COVID-19 : a systematic review and meta-analysis of 3377 patients", Blood, 136, pp.2881~2892 (2020)
3. Lee LYW, "COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics : a prospective cohort study", Lancet Oncol, 21, pp.1309~1316 (2020)
4. Singh N, "Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients", EJHaem, 1, pp.537~544 (2020)
5. Aksoy S, "Infectious complications of rituximab in patients with lymphoma during maintenance therapy : a systematic review and meta-analysis", Leuk Lymphoma, 50, pp.357~365 (2009)
6. Ghione P, "Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies", Blood, 138, pp.811~814 (2021)
7. Perry C, "Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma", Blood Adv, 5, pp.3053~3061 (2021)
8. Hong H, "The outcome of SARS-CoV-2 infection in patients with lymphoma and the risk factors for the development of pneumonia", Infect Chemother, 56, pp.378~385 (2024)
9. Nham E, "Vaccination Rates of Hospitalized Patients at High Risk of Severe COVID-19 : a single-center cross-sectional study", Infect Chemother, 54, pp.787~791 (2022)
10. Lee CM, "Impact of T-cell engagers on COVID-19-related mortality in B-cell lymphoma patients receiving B-cell depleting therapy", Cancer Res Treat, 56, pp.324~333 (2024)

관련 논문AI추천